The Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) raises awareness on all aspects of the antimicrobial resistance crisis. We talk to scientists and other stakeholders involved in the fight against AMR to create a library of information and further understanding.
Podcasts on the topic of diagnostics
A lot of diagnostic equipment has been developed but not much of it actually makes it to the market. On 11 May 2015 in London, the Medical Research Council UK and JPIAMR, hosted the workshop ‘Identifying the Pathway to Diagnostic Development’ to look at the route from bench to market of diagnostic development. Researchers from a wide range of disciplines, health care providers and professionals, industry, national and international policy makers and legislators have been invited to define and agree on a best practice process.
Arjon Van Hengel, Scientific Officer for Research Funding and Research Policy in the Area of Antimicrobial Resistance at the European Commission
Why do we need to be able to better diagnose disease to reduce antimicrobial resistance? Arjon Van Hengel explains.
Arjon Van Hengel studied biology at the University of Utrecht and received his PhD in molecular biology from the University of Wageningen. He then worked as a research scientist at the John Innes Centre in Norwich, UK. Since 2005, he works at the European Commission, first leading a research group that developed and validated analytical detection methods. Since 2009, he is working at the Directorate General for Research and Innovation.
Jorge Villacian, Chief Medical Officers at Janssen Diagnostics
Diagnostic tests provide a means to determine if a disease is caused by a bacteria or a virus for example. This leads to health carers being able to prescribe more targeted medication. Jorge Villacian shares the success story of how better diagnostics turned the tide for HIV sufferers and explains why diagnostics development in the field of antibacterial resistance is still lagging behind.
Jorge Villacian joined Johnson & Johnson as Director of Medical Affairs for Virco in Belgium in 2006. He holds an MD degree fro his home country Mexico, and specalised in Internal Medicine at the Mount Sinai Hospital in Miami and in Infectious Diseases at the Mayo Clinic in Rochester. Prior to joining Johnson & Johnson, Jorge led the clinical development of tipranavir (a protease inhibitor for treatment of resistant HIV) in Europe, Asia and Latin America with Boehringer Ingelheim in a programme that culminated in the approval of the drug for treatment of multi-resistant HIV.